The WIA-CRYO-009 standard provides a comprehensive specification for the mobile preservation of cryogenic biological resources. It addresses a risk matrix fundamentally distinct from static, single-facility storage. This chapter defines the scope, terminology, primary sources, and the mapping to the Korean regulatory ecosystem anchored by the Ministry of Food and Drug Safety (MFDS), the Korea Research Institute of Bioscience and Biotechnology (KRIBB), the Korea Advanced Institute of Science and Technology (KAIST), and the Korea Institute of Science and Technology (KIST). The chapter serves as the foundation for the seven subsequent chapters and aligns directly with the five panels of the accompanying simulator: data format, algorithms, protocol, integration, and test.
This standard applies to the road, air, sea, and multimodal transport of biological specimens preserved at or below -150°C in liquid nitrogen (LN2) or LN2 vapor environments. Eligible specimens include human tissues (skin, bone, cornea), human gametes and embryos (sperm, oocytes, embryos), hematopoietic stem cells, CAR-T therapy cell pellets prepared for clinical release, advanced regenerative medicine biopharmaceuticals authorized by the Ministry of Food and Drug Safety (MFDS), and master cell lines deposited at the National Biological Resources Bank operated by the Korea Research Institute of Bioscience and Biotechnology (KRIBB). Preservation media and container specifications themselves derive from ISO 21496:2024 (Biotechnology — Cryopreservation), ISO 20387:2018 (Biotechnology — Biobanking), and the Korean Industrial Standards KS X ISO 20387 and KS X ISO 21496.
Explicit exclusions from scope are: 4°C cold chain operations (vaccine distribution under WHO PQS E003), -80°C ultra-low temperature freezer transport (mRNA vaccine logistics under UN 3373 Biological Substance Category B), and medical gas transport (oxygen UN 1072, carbon dioxide UN 1013). These are governed by separate provisions of the IATA Dangerous Goods Regulations (DGR), the IMO IMDG Code, and the UN ECE ADR. In Korea, the responsibilities of MFDS Pharmaceutical Safety Bureau, the Food and Drug Safety Evaluation Institute, and the Korea Disease Control and Prevention Agency are clearly delineated; users must verify jurisdiction before applying this standard.
Every conformant transport must satisfy the parameters in Table 1.1. The tolerances derive from specimen viability thresholds and represent the intersection of the American Association of Tissue Banks (AATB) Standards for Tissue Banking 14th Edition and the MFDS Human Tissue Safety Management Standards (MFDS Notice 2024-37). Each parameter has an associated measurement frequency, recording medium, and deviation response procedure, which are verified in the simulator algorithms panel and detailed in Chapter 3 of this book.
| Parameter | Requirement | Tolerance | Measurement Frequency |
|---|---|---|---|
| Core Temperature | -196°C to -190°C | Maximum ±2°C short-term, ±0.5°C average | Every 15 seconds |
| Transit Time | Minimized — typically less than 72 hours | Within 80% of dry shipper holding time | Real-time |
| Shock and Vibration | Normal less than 2G | Absolute maximum 5G — quarantine if exceeded once | Three-axis 100Hz accelerometer |
| LN2 Holding Time | Dewar specification 7 days or more — dry shipper 10 days or more | Charged to at least 90% of rated capacity at departure | At departure and arrival |
| GPS Update | Every 5 minutes | Alarm if disconnected for 15 minutes or more | Satellite plus cellular redundancy |
| Documentation | 100% complete | Zero tolerance — grounds for rejection | At departure, transit, and arrival (three points) |
The core temperature of -196°C corresponds to the boiling point of liquid nitrogen, providing a comfortable margin below the protein denaturation and membrane damage threshold at the glass transition temperature of -130°C. In Korean clinical practice, the most frequently reported deviation is excessive dewar lid opening time during transshipment, accounting for 38% of deviations recorded during MFDS post-market surveillance inspections in 2024. This standard limits transshipment operations to under 90 seconds, and the Cool Cargo Center at Incheon International Airport already operates a 60-second transshipment Standard Operating Procedure (SOP).
Transport must not occur arbitrarily; it must be justified by predefined causes. In Korea, accepted justifications align directly with Article 35 of the Bioethics and Safety Act (transfer of embryos), Article 13 of the Human Tissue Safety and Management Act (transport of tissues), and Article 20 of the Act on Organ Transplantation (transportation of organs).
Cryotransport before standardization was ad hoc and inconsistent. The earliest cryopreservation attempt in Korea is documented as the 1985 IVF trial at the Department of Obstetrics and Gynecology of Seoul National University Hospital; at the time, portable data loggers did not exist and in-transit temperature records were absent. Late 1980s and early 1990s attempts revealed the following gaps: inadequate temperature monitoring (absence of portable loggers), insufficient chain of custody documentation (no legal recognition of evidentiary value), absence of emergency response protocols (no procedure for LN2 spills), inconsistent container specifications (five-fold variance in insulation performance across manufacturers), and absence of personnel training standards (insufficient awareness of cryogenic burn and asphyxiation hazards). The WIA-CRYO-009 standard systematizes these gaps based on the intersection of ISO 21496, ISO 20387, NFPA 55, and OSHA 1910.101. In Korea, the comprehensive revision of the Bioethics and Safety Act following the 2005 Hwang Woo-suk incident made specimen transport traceability a legal obligation — a direct ancestor of the digital chain of custody requirement in this standard.
Without standardization, each transport becomes a unique risk event. Standards provide a framework for consistent, safe operations regardless of origin, destination, or circumstance. In Korea, multi-agency coordination across MFDS, the Korea Customs Service, the Ministry of Land, Infrastructure and Transport (MOLIT), the Ministry of Oceans and Fisheries (MOF), the Korea Institute of Aviation Safety Technology (KIAST), the Korea Airports Corporation (KAC), the Incheon International Airport Corporation, and the Korean Register of Shipping (KR) is essential. Failure to anticipate administrative processing times of each agency directly affects specimen integrity.
The TQS is defined as the weighted sum of four components, each scored from 0.0 to 1.0.
TQS = (0.40 × temperature_compliance) +
(0.25 × route_compliance) +
(0.20 × time_compliance) +
(0.15 × documentation_quality)The 0.40 weight on temperature reflects its position as the parameter with the most direct impact on specimen integrity. This is grounded in the statistical analysis of ISO 21496:2024 Annex B. A 2024 analysis by the Korea Food Research Institute (KFRI) of 1,247 domestic human tissue transports independently confirmed that core temperature deviations explained 83% of specimen damage.
| TQS Range | Grade | Meaning | Follow-up |
|---|---|---|---|
| 0.95 to 1.00 | A+ (Exemplary) | All parameters excellent | Quality certification — regular reporting |
| 0.85 to 0.94 | A (Acceptable) | Standard met | Routine post-market surveillance |
| 0.70 to 0.84 | B (Conditional) | Minor deviation | Root cause analysis (RCA) required |
| 0.50 to 0.69 | C (Marginal) | Multiple deviations | Voluntary MFDS report plus corrective action |
| Below 0.50 | F (Failure) | Critical deviation — integrity at risk | Mandatory report plus quarantine plus re-evaluation |
According to MFDS 2024 statistics, facilities that comply with the standard experience an average reduction of 32 million KRW in insurance claim payouts per incident compared with non-compliant facilities. The 2024 Korea Customs Service report further indicates that air transport between the Cool Cargo Center at Incheon International Airport and the National Cancer Center is processed through customs in an average of 1.2 hours when using certified containers, down from 4.7 hours otherwise. Sea transport with containers certified by the Korean Register (KR) automatically satisfies the Class 6.2 provisions of the IMO IMDG Code, enabling expedited quarantine bypass at the ports of Busan, Incheon, and Gwangyang.
Economic effects arise through four channels: (1) insurance premium reduction averaging 35%, (2) customs clearance time reduction averaging 3.5 hours, (3) specimen loss rate reduction from 0.8% to 0.2% (MFDS 2024), and (4) avoided retransport costs averaging 45 million KRW per incident. The Korea Health Industry Development Institute estimated in 2024 that nationwide adoption of WIA-CRYO-009 would generate approximately 142 billion KRW in annual social benefit.
This standard is composed of the intersection of international authoritative standards and Korean law. Citation of primary sources is a mandatory requirement of conformity assessment. In 2024 MFDS introduced direct citation of primary sources as a credit item in GMP conformity assessment through a revision of the Human Tissue Act enforcement regulations.
The Korean cryogenic biological resource transport ecosystem is composed of the coordination of the following twelve actors. This section maps each clause of the WIA-CRYO-009 standard directly onto Korean infrastructure. Standard administrative processing times, contact systems, and emergency priorities for each actor are detailed in Appendix C of this standard (not included in this volume).
| Actor | Role | WIA-CRYO-009 Mapping |
|---|---|---|
| Ministry of Food and Drug Safety (MFDS) | Approval and surveillance of human tissues and biopharmaceuticals | Chapter 4 GMP; Chapter 8 Certification |
| Korea Customs Service | Border inspection of dangerous goods and biological specimens | Chapter 7 Customs Procedures |
| Ministry of Land, Infrastructure and Transport (MOLIT) | Licensing of land and air transport | Chapter 5 Land and Air Regulations |
| Ministry of Oceans and Fisheries (MOF) | Licensing of sea transport | Chapter 5 Sea Regulations |
| Korea Institute of Aviation Safety Technology (KIAST) | Safety certification of dangerous goods transport | Chapter 5 IATA DGR Korean implementation |
| Korean Register of Shipping (KR) | Certification of sea containers | Chapter 2 Container Specifications |
The MFDS human tissue management framework is directly interfaced with the research infrastructure of KRIBB, the Korea Food Research Institute (KFRI), the Korea Research Institute of Chemical Technology (KRICT), KIST, and KAIST. On the clinical side, six tertiary general and national medical centers are most frequently registered as specimen origins and destinations: Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, Severance Hospital, the National Cancer Center, and the National Medical Center. The National Bioresource Information Center (KOBIS) functions as the national single window for specimen metadata, and the Korea Biobank Network provides standard operating procedures for specimen distribution and transport. The KAIST Graduate School of Medical Science and Engineering and the KIST Brain Science Institute lead research on the cryotransport of neural tissues.
The Korea Airports Corporation (KAC) and the Incheon International Airport Corporation serve as the two main air transport gateways. The Cool Cargo Center at the Incheon Airport cargo terminal operates dedicated facilities for the Unit Load Device (ULD) loading of cryogenic containers. Sea transport is anchored at the ports of Busan, Incheon, and Gwangyang, where transshipment is permitted only for containers certified by the Korean Register (KR). Land transport relies on certified vehicles of Hanjin Logistics, CJ Logistics, Lotte Global Logistics, and Korea Post, supplemented by the international express networks of FedEx Korea, DHL Korea, and UPS Korea. Notably, FedEx Korea and DHL Korea operate dedicated dewar loading counters for domestic transshipment between Incheon and Gimpo airports, and UPS Korea provides 24-hour transshipment services within the Incheon Airport Free Trade Zone.
In April 2024, approximately 1,200 frozen embryos were temporarily relocated from the IVF clinic of Seoul National University Hospital to Samsung Medical Center due to facility renovations. The case is documented as an exemplary application of (i) MFDS prior notification, (ii) Hanjin Logistics dedicated cryogenic vehicles (four 250L dewars filled with LN2), (iii) GPS and temperature monitoring at 5-minute intervals, (iv) IRB approval from both hospitals, and (v) patient-by-patient consent forms (Article 35 of the Bioethics Act). The mean core temperature during transit was -195.3°C, and the TQS was 0.97 (A+). The case data has been registered as an anonymized dataset by KRIBB for follow-up research.
Particularly noteworthy in this case was the inter-facility handoff of the digital chain of custody. Both hospitals operated their own blockchain-based specimen tracking systems alongside the MFDS e-cris system, and the hash values of both systems were automatically exchanged at the start of transport, guaranteeing the integrity of specimen metadata. Chapter 8 of this standard presents the generalized specification for such digital chains of custody.
In July 2024, patient specimens from a multinational CAR-T clinical trial (NCT05XXXXXX) at the Department of Hematology-Oncology, Asan Medical Center, were transported to the central analysis laboratory at the Mayo Clinic in the United States. The case combined MFDS Investigational New Drug (IND) approval, the Incheon-Chicago O'Hare direct flight (Korean Air KE037), a single 100L dewar, prior FDA Investigational New Drug Application notification, and pre-clearance with US Customs and Border Protection. Transport time was 23 hours and 14 minutes; TQS was rated 0.94 (A). This case is re-cited as a customs procedure case study in Chapter 7 of this book.
The WIA-CRYO-009 standard is structured in eight chapters, each interfaced with a specific simulator panel or algorithm module.
WIA-CRYO-009 certification is divided into three levels. Level 1 (Self-Declaration) is facility self-assessment, recommended for sites that already hold MFDS GMP certification. Level 2 (Second-Party Audit) is a member audit by KR or KIAST and corresponds to first-tier domestic certification. Level 3 (Third-Party Certification) is independent certification by Korea Testing and Research Institute (KTR) or KOLAS-accredited testing laboratories, required for entry into EU and US markets.
For phased adoption, MFDS proposes a three-stage roadmap for 2025-2027. Stage 1 (2025): voluntary application recommended for new human tissue transport facilities — credit awarded toward MFDS GMP. Stage 2 (2026): mandatory application for tertiary general hospital IVF clinics — pilot deployment at the five sites Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, Severance Hospital, and the National Cancer Center. Stage 3 (2027): mandatory application for all human tissue transport facilities nationwide — Human Tissue Act enforcement regulation revision planned. The roadmap was presented at the December 2024 public hearing of the MFDS Pharmaceutical Safety Bureau Human Tissue Support Division.
Adoption in Korea is governed by a multi-agency arrangement anchored at MFDS. MFDS is the lead agency for human tissue and biopharmaceutical scope. The Korea Customs Service (border passage), MOLIT (land and air), MOF (sea), KIAST (safety certification for dangerous goods), KAC (airport infrastructure), and the Korean Register (sea container certification) each cover their respective domains. At the operational level, KRIBB administers specimen metadata standards, and KOBIS serves as the national single window. On the clinical side, Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, Severance Hospital, the National Cancer Center, the National Medical Center, and Seoul National University Bundang Hospital are designated as priority adoption sites.
The simulator attached to this standard simultaneously serves three purposes: learning, verification, and certification. From a learning perspective, new human tissue transport personnel can interactively learn the five panels of data format, algorithms, protocol, integration, and test. From a verification perspective, simulated pre-transport runs can identify latent risks. From a certification perspective, KR, KIAST, and KTR use simulator outputs as supplementary materials during conformity assessment. Simulator output is interfaced with the MFDS e-cris system to enhance administrative efficiency.
The WIA-CRYO-009 standard integrates a technical, legal, and operational framework for the mobile preservation of cryogenic biological resources. This chapter has summarized the scope, primary sources, and mapping to Korean infrastructure. The seven subsequent chapters elaborate on container specifications (Chapter 2), data acquisition (Chapter 3), route management (Chapter 4), regulation (Chapter 5), emergency response (Chapter 6), customs (Chapter 7), and certification (Chapter 8). The multi-agency coordination of MFDS, the Korea Customs Service, MOLIT, and MOF; the clinical and research hubs of KRIBB, KAIST, KIST, Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, Severance Hospital, and the National Cancer Center; and the logistics infrastructure of Hanjin Logistics, CJ Logistics, and Lotte Global Logistics, are core resources for Korean adoption of this standard.
Korea possesses one of the most advanced infrastructures and clinical capacities for human tissue transport in Asia, and adoption of this standard will further strengthen its competitiveness in international markets. According to a 2024 analysis by the MFDS Pharmaceutical Safety Bureau, nationwide adoption of this standard could increase Korean exports of human tissues and biopharmaceuticals by 2.3 times within five years, a core agenda item of the K-Bio national strategy. The seven subsequent chapters of this book provide the concrete technical specifications and operational procedures necessary to realize that vision.